Reunion Neuroscience Valuation
REUNDelisted Stock | USD 1.12 0.01 0.90% |
Today, the company appears to be overvalued. Reunion Neuroscience holds a recent Real Value of $0.86 per share. The prevailing price of the company is $1.12. Our model determines the value of Reunion Neuroscience from analyzing the company fundamentals such as Shares Outstanding of 11.72 M, return on equity of -0.86, and Shares Owned By Institutions of 50.65 % as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Reunion Neuroscience's price fluctuation is very steady at this time. Calculation of the real value of Reunion Neuroscience is based on 3 months time horizon. Increasing Reunion Neuroscience's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Reunion Neuroscience is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Reunion Stock. However, Reunion Neuroscience's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. Historical | Market 1.12 | Real 0.86 | Hype 1.12 | Naive 1.23 |
The intrinsic value of Reunion Neuroscience's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Reunion Neuroscience's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Reunion Neuroscience helps investors to forecast how Reunion stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Reunion Neuroscience more accurately as focusing exclusively on Reunion Neuroscience's fundamentals will not take into account other important factors: Reunion Neuroscience Total Value Analysis
Reunion Neuroscience is at this time anticipated to have valuation of (13.96 M) with market capitalization of 13.01 M, debt of 3.37 M, and cash on hands of 48.13 M. The negative valuation of Reunion Neuroscience may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Reunion Neuroscience fundamentals.Takeover Price | Market Cap | Debt Obligations | Cash |
(13.96 M) | 13.01 M | 3.37 M | 48.13 M |
Reunion Neuroscience Asset Utilization
One of the ways to look at asset utilization of Reunion is to check how much profit was generated for every dollar of assets it reports. Reunion Neuroscience holds a negative application of assets of -0.27 pct., losing $0.002651 for each dollar of assets held by the company. Inadequate asset utilization implies the company is being less effective with each dollar of assets it holds. Put it differently, asset utilization of Reunion Neuroscience shows how discouraging it operates for each dollar spent on its assets.Reunion Neuroscience Ownership Allocation
The market capitalization of Reunion Neuroscience is $13.01 Million. Over half of Reunion Neuroscience's outstanding shares are owned by third-party entities. These third-party entities are typically referred to as corporate investors that secure positions in a given instrument to benefit from reduced trade commissions. Note, that even with negative profits, if the true value of the company is larger than the current market value, you may still be able to generate positive returns on investment in this company.Reunion Neuroscience Profitability Analysis
Net Loss for the year was (48.49 M) with loss before overhead, payroll, taxes, and interest of (4.29 M).About Reunion Neuroscience Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Reunion Neuroscience. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Reunion Neuroscience based exclusively on its fundamental and basic technical indicators. By analyzing Reunion Neuroscience's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Reunion Neuroscience's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Reunion Neuroscience. We calculate exposure to Reunion Neuroscience's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Reunion Neuroscience's related companies.Field Trip Health Ltd. engages in the development and delivery of psychedelic- assisted therapies in North America. Field Trip Health Ltd. was founded in 2008 and is headquartered in Toronto, Canada. Reunion Neuroscience operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 194 people.
Reunion Neuroscience Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
Common Stock Shares Outstanding | 11.7 M | |
Shares Float | 2.8 M |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Other Consideration for investing in Reunion Stock
If you are still planning to invest in Reunion Neuroscience check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Reunion Neuroscience's history and understand the potential risks before investing.
Transaction History View history of all your transactions and understand their impact on performance | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
CEOs Directory Screen CEOs from public companies around the world | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data |